Calcineurin inhibitors

Mechanism of Action - T-Cell Takedown

• Calcineurin inhibitors (CNIs) block T-cell activation by halting the production of Interleukin-2 (IL-2), the primary cytokine for T-cell proliferation.
• They work by first binding to an intracellular protein (immunophilin):
  • Cyclosporine binds to Cyclophilin.
  • Tacrolimus binds to FKBP-12 (FK506 binding protein).
• This drug-immunophilin complex inhibits calcineurin, a phosphatase enzyme.
• Inhibition of calcineurin prevents the dephosphorylation of NFAT (Nuclear Factor of Activated T-cells).
• Without dephosphorylation, NFAT cannot translocate to the nucleus to promote IL-2 gene transcription.

⭐ A major advantage of calcineurin inhibitors is their lack of significant bone marrow suppression (myelosuppression), a common side effect of cytotoxic immunosuppressants.

The Inhibitors - Cyclosporine & Tacrolimus

• Mechanism of Action: Inhibit calcineurin, a phosphatase needed for T-cell activation.

  • This blocks the dephosphorylation of the Nuclear Factor of Activated T-cells (NFAT).
  • NFAT cannot enter the nucleus, thus inhibiting the transcription of IL-2.
  • Result: ↓ T-cell activation and proliferation.

• Cyclosporine:

  • Binds to cyclophilin.
  • 📌 Unique side effects: Gingival hyperplasia, Hirsutism, Hyperlipidemia.

• Tacrolimus (FK506):

  • Binds to FK-binding protein (FKBP).
  • More potent; higher risk of neurotoxicity and diabetes.

• Shared Major Toxicities:

  • ⚠️ Nephrotoxicity (most critical, dose-limiting).
  • Hypertension, hyperkalemia.

⭐ While both are highly nephrotoxic, Tacrolimus carries a greater risk for neurotoxicity and new-onset diabetes, whereas Cyclosporine is noted for causing gingival hyperplasia and hirsutism.

Clinical Uses - Taming the Immune System

• Solid Organ Transplant (SOT):
  • Primary use is prophylaxis against allograft rejection (kidney, liver, heart).
  • Typically part of a combination regimen with antimetabolites (e.g., mycophenolate) and corticosteroids.
• Autoimmune Conditions:
  • Rheumatoid Arthritis: For severe, refractory cases.
  • Psoriasis: For severe, recalcitrant disease.
  • Atopic Dermatitis: Topical tacrolimus and pimecrolimus are used for eczema.
• Graft-vs-Host Disease (GVHD):
  • Prophylaxis after hematopoietic stem cell transplantation.

⭐ Cyclosporine ophthalmic emulsion treats chronic dry eye (keratoconjunctivitis sicca) by ↓ inflammation and ↑ tear production.

Adverse Effects - The Price of Peace

• Nephrotoxicity: The most significant, dose-limiting toxicity. Causes afferent arteriolar vasoconstriction, leading to ↓ GFR. Initially reversible, but chronic use can cause irreversible interstitial fibrosis and tubular atrophy.
• Hypertension: Very common, resulting from renal vasoconstriction and sodium retention.
• Neurotoxicity: Presents as tremors (most common), headache, and rarely, seizures or PRES (Posterior Reversible Encephalopathy Syndrome). More common with tacrolimus.
• Metabolic Disturbances:
  • Hyperglycemia (risk of new-onset diabetes), especially with tacrolimus.
  • Hyperlipidemia
  • Hyperkalemia
• Drug-Specific Cosmetic Effects:
  • Cyclosporine: 📌 Gums & Hair Grow (Gingival hyperplasia & Hirsutism).
  • Tacrolimus: Hair Loss (Alopecia).

⭐ Calcineurin inhibitor-induced nephrotoxicity is primarily due to dose-dependent vasoconstriction of the afferent arterioles, a key mechanism tested on exams.

• Calcineurin inhibitors (Cyclosporine, Tacrolimus) prevent IL-2 transcription, thereby blocking T-cell activation.
• Primarily used for prophylaxis of solid organ transplant rejection and in various autoimmune disorders.
• Nephrotoxicity is the major dose-limiting toxicity for both agents.
• Common adverse effects include hypertension, neurotoxicity (tremor), and hyperglycemia.
• Cyclosporine is uniquely associated with gingival hyperplasia and hirsutism.
• Both are metabolized by CYP3A4, leading to significant drug-drug interactions.